The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration) to a process for preparing such a composition and to the use of such a composition for the treatment treatment and/or prevention of respiratory inflammatory or obstructive airway disease.

The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration), to a process for preparing such a composition and to the use of such a composition for the treatment treatment and/or prevention of respiratory, inflammatory or obstructive airway disease.

New polymorphic form of a long-acting beta-2 adrenoceptor agonist A new polymorphic form of arformoterol tartrate, designated as form D, is provided and which is characterised by at least one of the following: (i) a powder X-ray diffraction pattern having peaks at approximately 6.8, 13.3, 13.6, 3.8, 14.1, 18.2, 18.7, 20.0 +-0.2 degrees two theta

The present invention provides a process for preparing a compound of formula (Vl) or a salt thereof the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an α-haloketone of formula (III) to pr...

Disclosed is a process for preparing the (R,R)-diastereromer of a compound of formula (VI) or a salt thereof the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination and wherein the reductive amination is carried out in the presence of an ionic compound in an organic solven...

Provided herein is a highly pure arformoterol tartrate or an amorphous form thereof substantially free of desformyl impurity, 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]aniline, process for the preparation thereof, and pharmaceutical compositions comprising the highly pure arformoterol tartrate substantially free of the desformyl impurity.

Provided herein is a highly pure arformoterol tartrate or an amorphous form thereof substantially free of desformyl impurity 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]aniline process for the preparation thereof and pharmaceutical compositions comprising the highly pure arformoterol tartrate substantially free of the desformyl impurity.

Provided herein are improved convenient and industrially advantageous processes for the preparation of N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (Arformoterol) or a pharmaceutically acceptable salt thereof in high yield and purity. Provided further herein is an improved and industrially advantageous process for the preparation of a substantially enantiomerically pure arformoterol intermediate (R)-4-methoxy-α-methyl-N-(phenylmethy...

Provided herein are improved, convenient and industrially advantageous processes for the preparation of N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (Arformoterol) or a pharmaceutically acceptable salt thereof, in high yield and purity. Provided further herein is an improved and industrially advantageous process for the preparation of a substantially enantiomerically pure arformoterol intermediate, (R)-4-methoxy-[alpha]-methyl-N-(phenylme...